Orticumab
Orticumab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Orticumab Usage And Synthesis
Uses
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement[1][2].
in vivo
Orticumab (10 mg/mouse; i.p.; once weekly for 3 weeks) reduces atherosclerosis in the aortic arch, decreases the CD68-macrophage subvalvular plaque staining[1].
| Animal Model: | B6.lpr.ApoE-/- mice (18-week-old) fed with high-fat diet (HFD)[1] |
| Dosage: | 10 mg/mouse |
| Administration: | Intraperitoneal injection; once weekly for 3 weeks |
| Result: | Reduced atherosclerosis in the aortic arch by 42.8%, decreased the CD68-macrophage subvalvular plaque staining by 30.5%. |
References
[1] Yao Mattisson I, et al. Immune responses against oxidized LDL as possible targets for prevention of atherosclerosis in systemic lupus erythematosus. Vascul Pharmacol. 2021 Oct;140:106863. DOI:10.1016/j.vph.2021.106863
[2] Liang BC, et al. Compositions and methods with anti-ApoB100 antibody or fragment for treatment of psoriasis: World Intellectual Property Organization, WO2019232070 A1. 2019-12-05.
OrticumabSupplier
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com